Loading stock data…
UroGen Pharma Ltd. (URGN)
$43.81-0.28 (-0.62%)
Market ClosedLast close Sep 8
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
UroGen Pharma Ltd. in the Healthcare sector is trading at $43.81 with a market capitalization of $2.3B. Wall Street consensus targets $60.00 (8 analysts), implying a +36.9% move over the next 12 months. The stock is currently 14% below its 52-week high of $50.81, remaining 54.4% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +36.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $72.46M↑ | $50.96M↑ | $37.84M↑ | $27.48M↑ | $24.21M |
| Gross Profit | $65.88M↑ | $46.82M↑ | $34.55M↑ | $24.20M↑ | $20.66M |
| Operating Income | $111,000↑ | -$20.26M↓ | -$19.11M↑ | -$27.39M↑ | -$41.45M |
| Net Income | -$14.35M↑ | -$23.57M↑ | -$26.36M↑ | -$33.35M↑ | -$49.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technolog...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
73.75%
Volume
Today's trading volume
418,453
Recent News
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sector Update: Healthcare Stocks Mixed Monday Afternoon
Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
UroGen (URGN) Q2 2026 Earnings Call Transcript
ZUSDURI revenue hit $50.4M, growing 73% QoQ as adoption expands into community practices.
UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus
Why UroGen Pharma Stock Is Back in Focus After Q2 2026 Earnings UroGen Pharma (URGN) is back on investors radar after reporting second quarter 2026 results on 5 August, highlighted by higher reported sales and a smaller net loss for both the quarter and first half. The company reported Q2 sales of US$72.46 million with a net loss of US$14.35 million, and first half sales of US$123.42 million with a net loss of US$37.93 million, which may be reshaping sentiment around the stock. See our latest...